Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 281 participants.
Also called NCT04270760
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 281 participants
- Sponsor
- Registry
-
NCT04270760 -
2019-003688-23
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Denmark, Iceland, Japan, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT04270760. Randomized; double masking; primary purpose treatment. Start 2020-07-28 (actual); primary completion 2021-12-27 (actual). Results posted on 2023-08-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
- Condition
- Cardiovascular Disease
- Intervention (Drug)
- Olpasiran
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct04270760- Content hash
e03964024d9fc79e419274cc2fbef653d2a1f6a582aa1556081d15893e8f62a9